<DOC>
	<DOCNO>NCT00824733</DOCNO>
	<brief_summary>RATIONALE : Biological therapy , agatolimod , may stimulate immune system different way stop tumor cell grow . Monoclonal antibody , trastuzumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving agatolimod together trastuzumab may kill tumor cell . PURPOSE : This phase II trial study well give agatolimod together trastuzumab work treat patient locally advance metastatic breast cancer .</brief_summary>
	<brief_title>Agatolimod Trastuzumab Treating Patients With Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate progression-free survival patient HER2-overexpressing locally advance metastatic breast cancer treat trastuzumab ( Herceptin® ) agatolimod sodium . Secondary - To determine agatolimod sodium augments antibody-mediated cytoxicity ( ADCC ) trastuzumab-coated target cell evaluate ability patient immune-effector cell conduct ADCC produce interferon gamma . OUTLINE : This multicenter study . Patients receive trastuzumab ( Herceptin® ) IV 30-90 minute day 1 . Patients also receive agatolimod sodium subcutaneously day 15 22 course 1 day 1 , 8 , 15 , 22 subsequent course . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Blood sample collect periodically correlative laboratory study . Samples analyze antibody-mediated cytotoxicity ( ADCC ) chromium-release assay ; IFN-γ production quantification flow cytometry reverse transcriptase-polymerase chain reaction ( RT-PCR ) ; level cytokine ( IFN-γ TNF-α ) ELISA . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm breast cancer Locally advance metastatic disease HER2overexpressing tumor , define 3+ overexpression IHC and/or HER2 amplify FISH Nonmeasurable disease allow Achieved partial response , complete response , stable disease ( i.e. , disease progression ≥ 12 week ) trastuzumab ( Herceptin® ) chemotherapy , hormonal therapy alone , trastuzumab alone Last dose trastuzumab must administer within past 16 week No unstable brain metastasis Patients brain metastasis eligible provide stable ≥ 1 month surgery radiotherapy/radiosurgery AND corticosteroids anticonvulsant ≥ 4 week Hormone receptor status unspecified PATIENT CHARACTERISTICS : ECOG ( Eastern Cooperative Oncology Group ) performance status ( PS ) 02 ( Karnofsky PS 70100 % ) Absolute neutrophil count ≥ 1,500/mm³ Hemoglobin &gt; 8 g/dL ( transfusion/epoetin alfa allow ) Platelet count ≥ 100,000/mm³ Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN ( ≤ 5.0 time ULN know liver metastasis ) Creatinine &lt; 2 mg/mL Ejection fraction ≥ 50 % echocardiogram MUGA Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception , , ≥ 3 month completion study treatment No ongoing active infection require oral IV antibiotic No know autoimmune disorder antibodymediated disorder No know HIV positivity No known history hepatitis B C ( active and/or previously treat ) No malignancy within past 5 year except nonmelanoma skin cancer cervical cancer situ No history allergic reaction attribute compound similar chemical biologic composition study drug PRIOR CONCURRENT THERAPY : See Disease Characteristics More 12 week since prior chloroquine More 4 week since prior growth factor More 4 week since prior systemic corticosteroid More 4 week since prior chemotherapy , radiotherapy , monoclonal antibody therapy ( except trastuzumab ) No prior agatolimod sodium No prior allogeneic stem cell transplantation No prior continuous treatment singleagent trastuzumab &gt; 6 month No 3 prior chemotherapy regimens metastatic breast cancer Any number prior hormonal therapy allow No concurrent investigational agent monoclonal antibody No concurrent anticancer agent therapy Concurrent bisphosphonates skeletal metastasis allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>HER2-positive breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>